IVIG Dosing for Stevens-Johnson Syndrome
The evidence does not support routine use of IVIG for SJS, as high-quality guidelines and studies show no conclusive mortality benefit in adults, though if used, doses of ≥2 g/kg total appear most effective. 1
Key Guideline Recommendations
The 2016 UK guidelines for adults explicitly state there is no conclusive evidence demonstrating benefit of any intervention over conservative management alone, and high-quality multidisciplinary supportive care remains the priority. 1 The guidelines note a lack of consensus even among experienced clinicians regarding IVIG use, with strong advocates both for and against its use. 1
Evidence-Based Dosing When IVIG is Used
If IVIG is administered despite limited evidence, the following dosing patterns emerge from the literature:
Total Dose Considerations
- Meta-analysis demonstrates a strong inverse correlation between IVIG dosage and mortality, with doses ≥2 g/kg appearing to significantly decrease mortality. 2
- Most studies reporting potential benefit used total doses of 2 g/kg given over 2-5 days 1
- Common regimens include:
Pediatric Considerations
In children, some data suggest potential benefit, with systematic reviews showing good outcomes using 0.25-1.5 g/kg daily for 1-5 days, though this may simply reflect better prognosis in pediatric populations. 4 The 2019 British pediatric guidelines note that while consensus in adults is that IVIG lacks major impact, there is some data showing beneficial effects in children. 4
Critical Limitations and Contradictory Evidence
A high-quality prospective study by Bachot et al. showed no benefit from 2 g/kg IVIG, with progression of detachment in 22 of 34 cases and observed mortality (32%) exceeding predicted mortality (24%). 5 This study found no measurable effect on progression of detachment or speed of reepidermalization. 5
Lee et al. (2013) demonstrated no mortality difference between high-dose (>3 g/kg) versus low-dose (<3 g/kg) IVIG in 64 patients with SJS-TEN overlap or TEN. 1
Administration Parameters
When IVIG is used, standard infusion protocols apply:
- Initial rate: 0.01 mL/kg/min (0.5 mg/kg/min) 6
- Maximum rate if tolerated: 0.10 mL/kg/min (5 mg/kg/min) 6
- For patients at risk of renal dysfunction or thrombosis, use minimum dose and infusion rate practicable 6
Important Safety Considerations
IVIG carries significant risks including renal impairment, thrombosis, and in one pediatric series, higher rates of ophthalmic complications were observed in children given IVIG compared to those who were not. 4 The FDA labeling warns of thrombosis, renal dysfunction, and acute renal failure, particularly in patients with risk factors. 6
Ensure adequate hydration before administration and monitor renal function (BUN, creatinine, urine output) in at-risk patients. 6 Discontinue if renal function deteriorates. 6
Clinical Context
The guidelines emphasize that such interventions should ideally be practiced under supervision of a specialist skin failure multidisciplinary team in the context of a clinical study or case registry. 1 Recent data suggest anti-TNF agents show some promise and represent an active area of research. 4
Combination therapy with corticosteroids may provide better outcomes than either agent alone, with propensity-matched studies showing trends toward reduced mortality (SMR 0.38), shorter time to arrest progression (1.56 days), and lower infection rates. 7